Interface Biologics, Inc. is a commercial-stage company specializing in the development of advanced biomedical polymer technologies. These technologies are designed to improve the safety and effectiveness of medical devices and the targeted delivery of drugs. The company's core products include surface modification additives that are clinically proven to reduce infection and thrombus-related complications in FDA-cleared medical devices. Additionally, Interface Biologics offers sustained local drug delivery technologies applicable across various drug classes and medical specialties, with an initial focus on ophthalmology. The company primarily serves medical device manufacturers and pharmaceutical companies operating in the medtech and pharma markets. Interface Biologics generates revenue through the sale of its innovative materials and technologies, which are integrated into medical devices and drug delivery systems. The company’s team comprises chemists, engineers, and material scientists with extensive experience in managing industry growth.

Keywords: biomedical polymers, medical devices, drug delivery, surface modification, infection reduction, thrombus prevention, ophthalmology, FDA-cleared, medtech, pharma.